Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom improvement
RCT 4-armed trial	143 people with moderate to severe psoriasis	Decrease in Psoriasis Area and Severity Index scores from baseline 12 weeks 22% with pimecrolimus 10 mg 51% with pimecrolimus 20 mg 54% with pimecrolimus 30 mg 3% with placebo	P <0.01 for pimecrolimus 20 mg or 30 mg v placebo	Effect size not calculated	pimecrolimus